Researchers at the University of British Columbia have found a new way to block infection from the hepatitis C virus (HCV) in the liver that could lead to new therapies for those affected by this and other infectious diseases.

More than 170 million people worldwide live with hepatitis C, the disease caused by chronic HCV infection. HCV affects the liver and is spread by blood-to-blood contact. There is currently no vaccine to prevent it and treatments are only moderately effective and can cause serious side effects.

“As HCV infects a person, it needs fat droplets in the liver to form new virus particles,” says François Jean, Associate Professor in the Department of Microbiology and Immunology and Scientific Director of the Facility for Infectious Disease and Epidemic Research (FINDER) at UBC. “In the process, it causes fat to accumulate in the liver and ultimately leads to chronic dysfunction of the organ.”

“HCV is constantly mutating, which makes it difficult to develop antiviral therapies that target the virus itself,” says Jean. “So we decided to take a new approach.”

Jean and his team developed an inhibitor that decreases the size of host fat droplets in liver cells and stops HCV from “taking residence,” multiplying and infecting other cells.

“Our approach would essentially block the lifecycle of the virus so that it cannot spread and cause further damage to the liver,” says Jean. The team’s method is detailed in the journal PLoS Pathogens, published online today.

Bunny and BCCPD staff, Board and volunteers wish you all a very happy holiday and a peaceful New Year.

If you are planning on buying a mobility scooter and use HandyDART please be advised that the scooter cannot be more than 48 inches long and 37 inches wide. The combined weight of scooter and user cannot be more than 550 lbs. According to TransLink, these rules on the weight and dimensions of mobility devices have been in place since at least 1999.

Visit the TransLink website for more information on HandyDART.